| 產(chǎn)品名稱 | LY 2228820 |
| 產(chǎn)品貨號(hào) | Axon 1895 CAS [862505-00-8] MF C24H29FN6MW 420.53 Purity: 99% Soluble in DMSO Description Potent p38 MAPK inhibitor (IC50: 7 and 3 nM for p38α and p38β MAPKs respectively); antitumor agent for the treatment of multiple myeloma (MM) patients by reducing skeletal events and enhancing cytotoxicity of bortezomib (Axon 1810) References Certificates Categories Extra info K Ishitsuka et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br. J. Haematol. 2008, 141(5), 598-606. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology MAPK (p38) MAPK EC 2.7.11.24 Inhibitor of p38 MAPK Chemical name 5-(2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine Parent CAS No. [862505-00-8] Order Size Unit Price Stock 5 mg €105.00 In Stock |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
LY 2228820Axon 1895 CAS [862505-00-8] MF C24H29FN6
DescriptionPotent p38 MAPK inhibitor (IC50: 7 and 3 nM for p38α and p38β MAPKs respectively); antitumor agent for the treatment of multiple myeloma (MM) patients by reducing skeletal events and enhancing cytotoxicity of bortezomib (Axon 1810)
Inhibitor of p38 MAPK
Chemical name5-(2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine Parent CAS No.[862505-00-8] |
| 產(chǎn)品資料 |
